Search clinical trials for: CD4 CAR T cells

Total 2434 results

City of Hope Medical Center

Not yet recruiting

CMV-specific HIV-CAR T Cells as Immunotherapy for HIV/AIDS

HIV-1

United States
Chongqing Precision Biotech Co., Ltd

Recruiting

A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic Cancer

Gynecologic Cancer | Ovarian Cancer | Metastatic Cancer | Cervix Cancer | Advanced Cancer

China
Chongqing Precision Biotech Co., Ltd
The First Affiliated Hospital of Nanchang University

Recruiting

A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

Renal Cell Carcinoma | Ovarian Cancer | Metastatic Cancer | Cervix Cancer | Advanced Cancer

China
Shenzhen Geno-Immune Medical Institute
The Second Affiliated Hospital of Hainan Medical University; Beijing Jingdu...

Recruiting

Universal CAR-T Cells Targeting AML

Acute Myeloid Leukemia

China
Chongqing Precision Biotech Co., Ltd

Recruiting

A Clinical Research About CD70-positive Advanced/Metastatic Solid Tumors Treated by CD70-targeted CAR-T

Renal Cell Carcinoma | Ovarian Cancer | Cervix Cancer | Advanced Solid Tumor | Metastatic Tumor

China
PeproMene Bio, Inc.
City of Hope Medical Center

Recruiting

BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL

Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

United States
Beijing Immunochina Medical Science & Technology...

Recruiting

Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

China
Shenzhen Geno-Immune Medical Institute

Recruiting

Multiple CAR-T Cell Therapy Targeting AML

Acute Myeloid Leukemia

China
Chinese PLA General Hospital

Completed

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditions

China
Bacchetta, Rosa, MD
Food and Drug Administration (FDA); California Institute for Regenerative Medicine...

Recruiting

CD4^LVFOXP3 in Participants With IPEX

IPEX

United States
Shenzhen Geno-Immune Medical Institute
Shenzhen Children's Hospital; Shenzhen Hospital of Southern Medical University

Unknown

Immunotherapy Based on Antigen-specific Immune Effector Cells Targeting Neurofibromatosis or Schwannomatosis

Cancer

China
Beijing Immunochina Medical Science & Technology...
Peking University People's Hospital

Not yet recruiting

INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic Leukemia

Leukemia, B-cell
Weijia Fang, MD
Chongqing Precision Biotech Co., Ltd

Recruiting

A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

Renal Cell Carcinoma | Ovarian Cancer | Cervix Cancer | Advanced Solid Tumor | Metastatic Tumor

China
Chongqing Precision Biotech Co., Ltd

Recruiting

A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

Renal Cell Carcinoma | Ovarian Cancer | Cervix Cancer | Advanced Solid Tumor | Metastatic Tumor

China
Chongqing Precision Biotech Co., Ltd

Recruiting

Clinical Study of CD70-targeted CAR-T Therapy for Advanced/Advanced Renal Cancer

Renal Cell Carcinoma | Advanced Cancer | Metastatic Tumor

China
Chongqing Precision Biotech Co., Ltd

Recruiting

Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors

Stomach Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Recurrent Cancer | Metastatic Tumor

China
Weijia Fang, MD
Chongqing Precision Biotech Co., Ltd

Recruiting

A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors

Stomach Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Recurrent Cancer | Metastatic Tumor

China
PeproMene Bio, Inc.
City of Hope Medical Center

Recruiting

BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

United States
CARsgen Therapeutics Co., Ltd.
RenJi Hospital; First Affiliated Hospital of Zhejiang University

Completed

Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma

Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed B-cell Non-Hodgkin Lymphoma

China
First Affiliated Hospital of Zhejiang University

Unknown

An Exploratory Clinical Trial of Autologous Humanized Anti-cluster of Differentiation Antigen 19/20(CD19/CD20) Dual Specific CAR-T Cells Injection

Diffuse Large B Cell Lymphoma

China
Chinese PLA General Hospital

Unknown

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | Prolymphocytic Leukemia and other conditions

China
Cellular Biomedicine Group Ltd.

Recruiting

A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

China
Beijing Yongtai Ruike Biotechnology Company Ltd

Recruiting

CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL

Refractory B-cell Acute Lymphoblastic Leukemia | Relapsed B-cell Acute Lymphoblastic Leukemia

China
920th Hospital of Joint Logistics Support Force...

Recruiting

A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies

B-Cell Leukemia | B-Cell Lymphoma | B-cell Tumors

China
CARsgen Therapeutics Co., Ltd.
Fudan University

Recruiting

A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer

Pancreatic Cancer

China
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Radiation Therapy Before CAR T Cell Therapy for People With B Cell Lymphoma

Non-Hodgkin Lymphoma | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma Refractory

United States
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Terminated

A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma

Lymphoma, B-Cell

China
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Withdrawn

Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia

Refractory B Acute Lymphoblastic Leukemia | Relapse B Acute Lymphoblastic Leukemia

China
First Affiliated Hospital Xi'an Jiaotong University
Eureka Therapeutics Inc.

Unknown

Clinical Study of ET019002-T Cell Therapy for Refractory/Relapsed B-Cell Malignancies

B-Cell Malignancies
The First Affiliated Hospital of Guangdong Pharmaceutical...
University of Technology, Sydney; Guangzhou Anjie Biomedical Technology Co....

Unknown

Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC

Non-small Cell Lung Cancer | Lung Neoplasm Malignant

China
Porteus, Matthew, MD
California Institute for Regenerative Medicine (CIRM)

Recruiting

Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Adults With T-allo10 Cells Addback

Hematologic Diseases

United States
Luminary Therapeutics
The Cleveland Clinic; Case Western Reserve University

Recruiting

LMY-920 for Treatment of Relapsed or Refractory Myeloma (LMY-920-002)

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

United States
Ruijin Hospital
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

Unknown

Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma

Lymphoma

China
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma

Recurrent Glioblastoma | Recurrent Malignant Glioma | Recurrent WHO Grade III Glioma | Recurrent WHO Grade II Glioma

United States
Christian Hinrichs
National Cancer Institute (NCI)

Not yet recruiting

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

Cervical Cancer | HPV-Related Malignancy | Vulvar Cancer | Anal Cancer | Oropharynx Cancer | Vaginal Cancer | HPV-Related Carcinoma | HPV Positive Oropharyngeal Squamous Cell Carcinoma | Penile Cancer | HPV-Associated Cervical Carcinoma | HPV-Related Adenocarcinoma | HPV-Related Adenosquamous Carcinoma | HPV-Related... and other conditions

United States
Roger Williams Medical Center
Sirtex Medical

Completed

CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases (HITM-SIR)

Liver Metastases

United States
Shanghai Changzheng Hospital

Recruiting

Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease

Systemic Sclerosis | Sjogren's Syndrome | Antiphospholipid Syndrome | ANCA Associated Vasculitis | Systemic Lupus Erythematosus (SLE) | Inflammatory Myopathy

China
Chimeric Therapeutics

Not yet recruiting

A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy

Gastric Cancer | Colorectal Cancer | Neuroendocrine Tumors
Chongqing Precision Biotech Co., Ltd
Shanxi Bethune Hospital

Recruiting

CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors

Breast Cancer | Gastric Cancer | Esophageal Cancer | Lung Cancer | Rectal Cancer | Colon Cancer | Pancreas Cancer

China
Chongqing Precision Biotech Co., Ltd

Recruiting

Safety and Efficacy of CEA-targeted CAR-T for CEA-positive Advanced Malignant Solid Tumors

Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer

China
Ruijin Hospital
UTC Therapeutics Inc.

Recruiting

Anti-mesothelin CAR-T Cells With Advanced Refractory Solid Tumors (Amaretto)

Refractory Malignant Solid Neoplasm

China
China Meitan General Hospital
Marino Biotechnology Co., Ltd.

Unknown

Anti-mesothelin CAR T Cells for Patients With Recurrent or Metastatic Malignant Tumors

Mesothelin Positive Tumors

China
Shanghai Ming Ju Biotechnology Co., Ltd.

Recruiting

A Phase 1, Single-arm, Open-label, Dose-escalation Study of JWATM204 as T Cell-targeted Immunotherapy in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma

Liver Carcinoma | Hepatic Cell Carcinoma

China
Chongqing Precision Biotech Co., Ltd
Zhejiang University

Recruiting

A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors

Breast Cancer | Gastric Cancer | Colorectal Cancer | Bile Duct Cancer | Non-small Cell Lung Cancer | Pancreas Cancer | Esophagus Cancer

China
Chinese PLA General Hospital
UTC Therapeutics Inc.

Recruiting

CD70 Targeted CAR-T Cells in CD70 Positive Advanced/Metastatic Solid Tumors

Solid Tumor, Adult

China
Chinese PLA General Hospital
UTC Therapeutics Inc.

Recruiting

CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma

Lymphoma

China
Wuhan Union Hospital, China
Shanghai Cell Therapy Group Co.,Ltd

Unknown

αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors

Non-small-cell Lung Cancer | Mesothelioma

China
Chinese PLA General Hospital

Unknown

Study of PD-1 Gene-knocked Out Mesothelin-directed CAR-T Cells With the Conditioning of PC in Mesothelin Positive Multiple Solid Tumors

Solid Tumor, Adult

China
George Papanicolaou Hospital
General Hospital Of Thessaloniki Ippokratio

Recruiting

Generation of SARS-CoV-2-specific T Lymphocytes From Recovered Donors and Administration to High-risk COVID-19 Patients (CoV-2-STs)

Severe COVID-19

Greece
Xijing Hospital

Unknown

CD147-CART Cells in Patients With Recurrent Malignant Glioma.

Recurrent Glioblastoma | CD147 Positive

China

Search clinical trials for: CD4 CAR T cells

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uganda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations